Literature DB >> 28478120

Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease.

George B McDonald1, Laura Tabellini2, Barry E Storer3, Paul J Martin1, Richard L Lawler2, Steven L Rosinski1, H Gary Schoch2, John A Hansen1.   

Abstract

We examined the hypothesis that plasma biomarkers and concomitant clinical findings after initial glucocorticoid therapy can accurately predict failure of graft-versus-host-disease (GVHD) treatment and mortality. We analyzed plasma samples and clinical data in 165 patients after 14 days of glucocorticoid therapy and used logistic regression and areas under receiver-operating characteristic curves (AUC) to evaluate associations with treatment failure and nonrelapse mortality (NRM). Initial treatment of GVHD was unsuccessful in 49 patients (30%). For predicting GVHD treatment failure, the best clinical combination (total serum bilirubin and skin GVHD stage: AUC, .70) was competitive with the best biomarker combination (T cell immunoglobulin and mucin domain 3 [TIM3] and [interleukin 1 receptor family encoded by the IL1RL1 gene, ST2]: AUC, .73). The combination of clinical features and biomarker results offered only a slight improvement (AUC, .75). For predicting NRM at 1 year, the best clinical predictor (total serum bilirubin: AUC, .81) was competitive with the best biomarker combination (TIM3 and soluble tumor necrosis factor receptor-1 [sTNFR1]: AUC, .85). The combination offered no improvement (AUC, .85). Infection was the proximate cause of death in virtually all patients. We conclude that after 14 days of glucocorticoid therapy, clinical findings (serum bilirubin, skin GVHD) and plasma biomarkers (TIM3, ST2, sTNFR1) can predict failure of GVHD treatment and NRM. These biomarkers reflect counter-regulatory mechanisms and provide insight into the pathophysiology of GVHD reactions after glucocorticoid treatment. The best predictive models, however, exhibit inadequate positive predictive values for identifying high-risk GVHD cohorts for investigational trials, as only a minority of patients with high-risk GVHD would be identified and most patients would be falsely predicted to have adverse outcomes.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic; Biomarker; Cause of death; Graft-versus-host disease; Hematopoietic cell transplantation; Marrow transplantation; Mortality; Outcomes; Positive predictive value; Treatment failure

Mesh:

Substances:

Year:  2017        PMID: 28478120      PMCID: PMC5555298          DOI: 10.1016/j.bbmt.2017.04.029

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  41 in total

1.  Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation.

Authors:  Yi-Bin Chen; Haesook T Kim; Sean McDonough; Robert D Odze; Xiaopan Yao; Suzan Lazo-Kallanian; Thomas R Spitzer; Robert Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Biol Blood Marrow Transplant       Date:  2009-07-08       Impact factor: 5.742

2.  Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine.

Authors:  Elisha Waldman; Sydney X Lu; Vanessa M Hubbard; Adam A Kochman; Jeffrey M Eng; Theis H Terwey; Stephanie J Muriglan; Theo D Kim; Glenn Heller; George F Murphy; Chen Liu; Onder Alpdogan; Marcel R M van den Brink
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

Review 3.  Discovery and validation of graft-versus-host disease biomarkers.

Authors:  Sophie Paczesny
Journal:  Blood       Date:  2012-11-19       Impact factor: 22.113

4.  Development of a biomarker scoring system for use in graft-versus-host disease.

Authors:  Anne S Renteria; John E Levine; James L Ferrara
Journal:  Biomark Med       Date:  2016-07-14       Impact factor: 2.851

5.  Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.

Authors:  Shernan G Holtan; Michael R Verneris; Kirk R Schultz; Laura F Newell; Gabrielle Meyers; Fiona He; Todd E DeFor; Gregory M Vercellotti; Arne Slungaard; Margaret L MacMillan; Sarah A Cooley; Bruce R Blazar; Angela Panoskaltsis-Mortari; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-07       Impact factor: 5.742

Review 6.  Role of the intestinal mucosa in acute gastrointestinal GVHD.

Authors:  Jonathan U Peled; Alan M Hanash; Robert R Jenq
Journal:  Blood       Date:  2016-11-17       Impact factor: 22.113

7.  Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation.

Authors:  Ted A Gooley; Pankaj Rajvanshi; H Gary Schoch; George B McDonald
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

8.  A novel soluble form of Tim-3 associated with severe graft-versus-host disease.

Authors:  John A Hansen; Samir M Hanash; Laura Tabellini; Chris Baik; Richard L Lawler; Bryan M Grogan; Barry Storer; Alice Chin; Melissa Johnson; Chee-Hong Wong; Qing Zhang; Paul J Martin; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2013-06-17       Impact factor: 5.742

9.  Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment.

Authors:  George B McDonald; Laura Tabellini; Barry E Storer; Richard L Lawler; Paul J Martin; John A Hansen
Journal:  Blood       Date:  2015-05-18       Impact factor: 22.113

10.  Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration.

Authors:  Caroline A Lindemans; Marco Calafiore; Anna M Mertelsmann; Margaret H O'Connor; Marcel R M van den Brink; Alan M Hanash; Jarrod A Dudakov; Robert R Jenq; Enrico Velardi; Lauren F Young; Odette M Smith; Gillian Lawrence; Juliet A Ivanov; Ya-Yuan Fu; Shuichiro Takashima; Guoqiang Hua; Maria L Martin; Kevin P O'Rourke; Yuan-Hung Lo; Michal Mokry; Monica Romera-Hernandez; Tom Cupedo; Lukas Dow; Edward E Nieuwenhuis; Noah F Shroyer; Chen Liu; Richard Kolesnick
Journal:  Nature       Date:  2015-12-09       Impact factor: 49.962

View more
  13 in total

Review 1.  Biomarkers for posttransplantation outcomes.

Authors:  Sophie Paczesny
Journal:  Blood       Date:  2018-04-05       Impact factor: 22.113

Review 2.  Post-haematopoietic cell transplantation outcomes: why ST2 became a 'golden nugget' biomarker.

Authors:  Sophie Paczesny
Journal:  Br J Haematol       Date:  2020-02-10       Impact factor: 6.998

3.  Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD.

Authors:  Sarah A Wall; Qiuhong Zhao; Martha Yearsley; Luke Blower; Akwasi Agyeman; Parvathi Ranganathan; Shangbin Yang; Haiwa Wu; Matthew Bostic; Samantha Jaglowski; Jonathan E Brammer; Basem William; Hannah Choe; Alice S Mims; Sam Penza; Yvonne Efebera; Steven Devine; Spero Cataland; Stella M Davies; Sumithira Vasu
Journal:  Blood Adv       Date:  2018-10-23

Review 4.  Current Definitions and Clinical Implications of Biomarkers in Graft-versus-Host Disease.

Authors:  Alan Bidgoli; Brittany Paige DePriest; Maedeh Vakili Saatloo; Hua Jiang; Denggang Fu; Sophie Paczesny
Journal:  Transplant Cell Ther       Date:  2022-07-11

5.  MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.

Authors:  Hannah Major-Monfried; Anne S Renteria; Attaphol Pawarode; Pavan Reddy; Francis Ayuk; Ernst Holler; Yvonne A Efebera; William J Hogan; Matthias Wölfl; Muna Qayed; Elizabeth O Hexner; Kitsada Wudhikarn; Rainer Ordemann; Rachel Young; Jay Shah; Matthew J Hartwell; Mohammed S Chaudhry; Mina Aziz; Aaron Etra; Gregory A Yanik; Nicolaus Kröger; Daniela Weber; Yi-Bin Chen; Ryotaro Nakamura; Wolf Rösler; Carrie L Kitko; Andrew C Harris; Michael Pulsipher; Ran Reshef; Steven Kowalyk; George Morales; Ivan Torres; Umut Özbek; James L M Ferrara; John E Levine
Journal:  Blood       Date:  2018-03-15       Impact factor: 22.113

Review 6.  Biomarkers for Early Complications After Hematopoietic Stem Cell Transplantation.

Authors:  Courtney M Rowan; Sophie Paczesny
Journal:  Clin Lab Med       Date:  2018-12-18       Impact factor: 1.935

7.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report.

Authors:  Joseph Pidala; Carrie Kitko; Stephanie J Lee; Paul Carpenter; Geoffrey D E Cuvelier; Shernan Holtan; Mary E Flowers; Corey Cutler; Madan Jagasia; Ted Gooley; Joycelynne Palmer; Tim Randolph; John E Levine; Francis Ayuk; Fiona Dignan; Helene Schoemans; Eric Tkaczyk; Nosha Farhadfar; Anita Lawitschka; Kirk R Schultz; Paul J Martin; Stefanie Sarantopoulos; Yoshihiro Inamoto; Gerard Socie; Daniel Wolff; Bruce Blazar; Hildegard Greinix; Sophie Paczesny; Steven Pavletic; Geoffrey Hill
Journal:  Transplant Cell Ther       Date:  2021-04-06

8.  Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study.

Authors:  Ran Reshef; Wael Saber; Javier Bolaños-Meade; George Chen; Yi-Bin Chen; Vincent T Ho; Doris M Ponce; Ryotaro Nakamura; Michael J Martens; John A Hansen; John E Levine
Journal:  J Clin Oncol       Date:  2021-01-28       Impact factor: 50.717

Review 9.  Biomarkers in Graft-Versus-Host Disease: from Prediction and Diagnosis to Insights into Complex Graft/Host Interactions.

Authors:  Fiona C He; Shernan G Holtan
Journal:  Curr Hematol Malig Rep       Date:  2018-02       Impact factor: 4.213

Review 10.  Biomarkers for Allogeneic HCT Outcomes.

Authors:  Djamilatou Adom; Courtney Rowan; Titilayo Adeniyan; Jinfeng Yang; Sophie Paczesny
Journal:  Front Immunol       Date:  2020-04-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.